Activartis Biotech GmbH
Activartis was founded as a spin-off of the St. Anna CCRI, in 2003. From 2006-2013 it was a subsidiary of AOP Orphan AG, Vienna, Austria, and is currently owned by a group of investors. Thomas Felzmann, now Activartis’ CEO, and his team developed Activartis’ proprietary AV0113 dendritic cell (DC) cancer immunotherapy (CIT) technology. The immune checkpoint inhibitor (ICP) programme started resulted in patents for an RNAi- and a small molecule techechnology platform.